In ALK rearranged NSCLC, the aim of ALK directed vaccines is to convert the immunosuppressive TME into an immunoreactive TME, thereby stimulating the migration of TILs to the tumour microenvironment to kill tumour cells (122). This evidence concerns the gene ALK and non-small cell lung carcinoma.